Eurofins Viracor BioPharma Services, a partner for clinical trial testing solutions, is expanding its service portfolio with enhanced bioanalytical testing capabilities fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP). This expansion enables the company to enhance support of biopharmaceutical development programs with greater scientific breadth throughout the drug development workflow.

This strategic advancement follows the successful relocation and integration of Eurofins Pharma Bioanalytics Services from St. Charles, Missouri, into Eurofins Viracor BioPharma’s purpose‑built facility in Lenexa, Kansas. The bioanalytical organization brings more than two decades of specialized experience in pharmacokinetics, immunogenicity, and biomarker testing. By combining both laboratories’ strengths, Eurofins Viracor BioPharma expands the depth of scientific expertise available to sponsors while simplifying access to integrated technologies, harmonized contracting, and comprehensive testing solutions under one unit; providing sponsors with more seamless and efficient experience.

The newly expanded laboratory space in Lenexa was designed to meet the needs of increasingly complex clinical trials, ensuring high‑quality sample management, streamlined workflows, and robust data integrity. With these enhanced capabilities, Eurofins Viracor BioPharma now offers a full suite of bioanalytical services, including method development, validation, and regulated sample analysis, all consistent with global regulatory guidance.